UNSPSC 51182431: Ipriflavone

This classification denotes a nutritional supplement and flavonoid with the molecular formula C18H16O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80BJ7WN25Z, chemically known as 4h-1-benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl- but generally known as ipriflavone, which bears US NIH Compound Identifier 3747. European Medicines Agency schedules Ipriflavone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08278MIG. The term IPRIFLAVONE is an International Non-Proprietary Name.

UNSPSC 51182431 Ipriflavone is a Commodity code capturing pharmaceutical products supplied through state and local cooperative purchasing arrangements. State and local governments buy generic multi-source pharmaceuticals and over-the-counter products under this code, procuring through authorized wholesaler networks with specified National Drug Codes, SKUs, and manufacturing certifications. The issuing bodies include state agencies and multistate cooperative purchasing alliances administering contracts for distribution across participating state and local government facilities, with the Minnesota Department of Administration's Office of State Procurement serving as administrator for one active vehicle covering multiple jurisdictions. Work under the code involves manufacturers submitting comprehensive product specifications, pricing in multiple formats (flat price, net price, or WAC-minus structures), and maintaining compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act while establishing relationships with authorized wholesalers maintaining chargeback systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has posted the primary recent opportunity under this code: a Request for Proposal issued January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract effective date. The procurement covers participating state and local facilities across Minnesota and Oregon, requiring vendors to distribute through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and maintain insurance including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability. Evaluation weighs price competitiveness at 75 percent, with secondary scoring on fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee; contract terms run two years for new vendors with optional extensions and existing terms through June 30, 2028 for incumbents.